SR 76 — A resolution to recognize October 2025 as Uterine Fibroids Awareness Month.

SR-76,MICHIGAN As Adopted by Senate, October 8, 2025 SENATE RESOLUTIONSenate NO.Resolution No.

76 Offered by Senators Anthony, Geiss and Polehanki offeredA RESOLUTION TO RECOGNIZE OCTOBER 2025 AS UTERINE FIBROIDS AWARENESS MONTH WHEREAS, Uterine fibroids, also known as leiomyomas or myomas, are non-cancerous growths that form in or around the followinguterus resolution:or pelvic cavity that can lead to significant pelvic pain, reproductive dysfunction, abnormal uterine bleeding, miscarriages, and infertility;

Aand resolutionWHEREAS, Uterine fibroids can vary in number, size, and severity depending on the location and sometimes lead to recognizedistortion Octoberof 2025the asinside Uterineand Fibroidsoutside Awarenessof Month.the uterus, or in some cases, can cause extreme pain when a fibroid outgrows its blood supply and starts to die, ultimately leading to more serious health complications;

Whereas,and UterineWHEREAS, fibroids,The alsopain, knowndiscomfort, asstress, leiomyomasand orother myomas,physical areand non-cancerousemotional growthssymptoms thatof formliving inwith orfibroids aroundmay theinterfere uteruswith ora pelvicwoman’s cavityquality thatof canlife, leadaffecting totheir significantpersonal pelvicand pain,professional reproductivelife, dysfunction,as abnormalwell uterineas bleeding,their miscarriages,overall health and infertility;well-being;

and Whereas,WHEREAS, Uterine fibroids canare varyone inof number, size, and severity depending on the locationmost andcommon sometimesmedical leadconditions toamong distortionwomen, ofwith thean insideestimated and26 outsidemillion ofwomen the uterus, or in somethe cases,United canStates cause(U.S.) extremeimpacted painduring whentheir areproductive fibroidyears, outgrowswith itsthe bloodlikelihood supplyof anddeveloping startsthe tocondition die,increasing ultimatelywith leadingage; to more serious health complications;

and UterineWHEREAS, Fibroids_SR76_AA_1Despite naxj4dtheir 1prevalence, Whereas,statistics Theon pain,uterine discomfort, stress, and other physical and emotional symptoms of living with fibroids mayare interfereoften withunderestimated, aas woman’smany qualitywomen ofremain life,undiagnosed affectingor theirdo personalnot andseek professionalmedical life,care. as well as their overall health and well-being;

and Whereas, Uterine fibroids are one of the most common medical conditions among women, with an estimated 26 million women in the United States (U.S.) impacted during their reproductive years, with the likelihood of developing the condition increasing with age;

and Whereas, Despite their prevalence, statistics on uterine fibroids are often underestimated, as many women remain undiagnosed or do not seek medical care.

and Whereas,WHEREAS, Uterine fibroids disproportionately impact women of color, as Black women are diagnosed with fibroids roughly three times as frequently as Caucasian women, with women of color being more prone to develop the condition earlier in life and tend to experience larger and more numerous fibroids that cause more severe symptoms;

and Whereas,WHEREAS, The diagnosis of fibroids starts with detection during a routine pelvic exam, but can lead to more complex testing, including a pelvic ultrasound, magnetic resonance imaging (MRI), hysterosalpingography, or hysteroscopy;

and Whereas,WHEREAS, A woman’s fertility can be affected by uterine fibroids in a variety of ways, including the possibility of the fibroids growing and blocking the uterus or fallopian tubes, making it harder to become pregnant.

Other negative impacts include miscarriages, abnormal attachment of the placenta, increased likelihood of delivery by cesarean section, and postpartum Uterine Fibroids_SR76_AA_1 naxj4d 1 hemorrhage;

and Whereas,WHEREAS, Treatments for uterine fibroids range from medicinal to surgical approaches, depending on the severity of the case, symptoms, location and size of the fibroids, age, medical history, and a woman’s health goals.

Medicinal approaches include anti-anti-inflammatory inflammatory painkillers and hormonal treatments like oral contraceptive pills or progesterone-containing agents.

and Whereas,WHEREAS, A hysterectomy, defined as the surgical removal of the uterus, remains one of the most frequently performed procedures for the treatment of uterine fibroids.

and Whereas,WHEREAS, The number of U.S.

and Whereas,WHEREAS, A recent study showed the total annual economic burden of uterine fibroids in the U.S.

is estimated at $42.2$42.2 billion, billion, including direct medical costs, lost work productivity due to absenteeism and short-term disability among women ages 25–54,25-54, cesarean-related obstetrical expenses, and infertility-related treatment costs;

and WhereasWHEREAS Public awareness and education about uterine fibroids is critical to increase knowledge about this condition and improve prevention, screening, diagnosis, and treatment methods;

now, therefore, be it ResolvedRESOLVED byBY theTHE Senate,SENATE, That the members of this legislative Uterine Fibroids_SR76_AA_1 naxj4d body recognize October 2025 as Uterine Fibroids Awareness Month.

UterineAdopted Fibroids_SR76_AA_1by naxj4dthe Senate, October 8, 2025.

Secretary of the Senate